文献速递淋巴瘤

Copanlisib单药治疗分子定义的复发或难治性弥漫性大B细胞淋巴瘤的活性

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2020-02-14

本研究评估了磷脂酰肌醇3-激酶抑制剂copanlisib在复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)患者中的疗效与安全性,并分析疗效与细胞起源(COO;ABC和GCB)及其他生物标志物的关系。CD79B突变型与野生型ORR分别为22.2%和20.0%。中位无进展生存期和缓解持续时间分别为1.8个月和4.3个月。安全性可控,常见不良事件为高血压、腹泻和高血糖。

要点

  • Copanlisib在复发/难治性DLBCL中显示单药活性,ORR为19.4%。
  • ABC亚型ORR(31.6%)数值上高于GCB亚型(13.3%)。
  • 常见不良事件包括高血压(40.3%)、腹泻(37.3%)和高血糖(32.8%)。

核心结论

  • Copanlisib单药在复发/难治性DLBCL中具有可管理的安全性,且在ABC亚型中观察到数值上更高的缓解率。

主要发现

  • 总体ORR为19.4%;ABC DLBCL患者ORR为31.6%,GCB DLBCL患者为13.3%。
  • CD79B突变型与野生型患者的ORR分别为22.2%和20.0%。
  • 总体中位无进展生存期为1.8个月,中位缓解持续时间为4.3个月。
  • 常见不良事件包括高血压(40.3%)、腹泻(37.3%)和高血糖(32.8%)。
  • 检测到338个基因异常,包括BCL2(53.7%)和MLL2(53.7%),并识别出一个可区分缓解者与非缓解者的16基因特征。

关键数值与推荐

  • 主要终点为DLBCL COO亚组(ABC、GCB、不可分类)和CD79B突变状态下的客观缓解率(ORR)。

临床怎么用

  • 对于复发/难治性DLBCL,copanlisib单药可作为考虑选项之一,尤其在ABC亚型中可能具有更高缓解潜力。
  • 治疗期间需监测高血压、腹泻和高血糖等不良事件。

局限性

  • 研究为单臂设计,缺乏随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of origin (COO; activated B-cell like [ABC] and germinal center B-cell like [GCB]) and other biomarkers. The primary endpoint was objective response rate (ORR) in DLBCL COO subgroups (ABC, GCB, and unclassifiable) and by CD79B mutational status (NCT02391116). Sixty-seven patients received copanlisib (ABC DLBCL, n = 19; GCB DLBCL, n = 30; unclassifiable, n = 3; missing, n = 15). The ORR was 19.4%; 31.6% and 13.3% in ABC and GCB DLBCL patients, respectively. ORR was 22.2%/20.0% for patients with/without CD79B mutations (wild type, n = 45; mutant, n = 9; missing, n = 13). Overall median progression-free survival and duration of response were 1.8 and 4.3 months, respectively. Adverse events included hypertension (40.3%), diarrhea (37.3%), and hyperglycemia (32.8%). Aberrations were detected in 338 genes, including BCL2 (53.7%) and MLL2 (53.7%). A 16-gene signature separating responders from nonresponders was identified. Copanlisib treatment demonstrated a manageable safety profile in patients with relapsed/refractory DLBCL and a numerically higher response rate in ABC vs. GCB DLBCL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lenz G, Hawkes E, Verhoef G, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020. PMID: 32060403. doi:10.1038/s41375-020-0743-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。